In its financial results for 2021, released Wednesday, Takeda announced that it has decided to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,